Taiwan FDA registration f5ff0d2a9d323e0aa613b2ad66e72ca3
"Nasling" prognostic gene imprinting detection system for breast cancer
TW: “納斯凌”普芯娜乳癌預後基因印記檢測系統
Taiwan·Risk Class 2·VERACYTE, INC.;; Veracyte·Registered Dec 21, 2018 – Dec 21, 2028ActiveRegistration details
- Analysis ID
- f5ff0d2a9d323e0aa613b2ad66e72ca3
- Customs Code
- DHA05603198701
Company information
- Manufacturer
- VERACYTE, INC.;; Veracyte
- Manufacturer Country
- France;;United States
- Authorized Representative
- COLD SPRING BIOTECH CORP.
Product details
- Intended Use
- As detailed as Chinese imitation order.
- Product Type (Level 1)
- C Immunology and microbiology
- Product Type (Level 2)
- C.6040 乳癌癒後基因表現測試系統
- Import Information
- import
Dates and status
- Registration Date
- Dec 21, 2018
- Expiry Date
- Dec 21, 2028
About this record
Access comprehensive regulatory information for "Nasling" prognostic gene imprinting detection system for breast cancer in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number f5ff0d2a9d323e0aa613b2ad66e72ca3 and manufactured by VERACYTE, INC.;; Veracyte. The authorized representative in Taiwan is COLD SPRING BIOTECH CORP..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices